Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a micro-cap biotech player pushing its way onto the pancreatic cancer treatment scene. The company was recently featured in a Stock Market Media Group piece that helps to better define the company’s message. The basic gist of that message positions PMCB as an emerging direct competitor with Ely Lilly (LLY) and its chemotherapy drug, gemcitabine.
PharmaCyte’s alternative is to use its advanced, inoperable pancreatic cancer therapy, “which consists of the company’s signature live-cell encapsulation technology, Cell-in-a-Box, plus low doses of the FDA-approved chemotherapy drug ifosfamide, in its upcoming clinical trial where it will go head to head with gemcitabine in order to address an unmet medical need.”
Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer.
It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer-based upon the constituents of the Cannabis plant.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.
According to company materials, “PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.”
Find out when $PMCB stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to the release, “Dr. Von Hoff and his firm Translational Drug Development (TD2) will now help PharmaCyte with its pancreatic cancer therapy in an upcoming clinical trial that he helped design along with Dr. Manuel Hidalgo, who is the Chief of the Division of Hematology-Oncology at Harvard Medical School’s Beth Israel Deaconess Medical Center and who will serve as the Principal Investigator in PharmaCyte’s upcoming clinical trial, and Dr. Matthias Löhr of the Karolinska Institute in Stockholm, Sweden.”
The piece goes on to note that “Dr. Von Hoff helped to get approval for Celgene’s Abraxane-gemcitabine combination fast-tracked by showing the FDA that there is an urgent need for better treatments for advanced pancreatic cancer, and there is a real opportunity that PharmaCyte’s therapy could also be fast-tracked if the company can produce data that is similar or better than the data produced in two earlier independent clinical trials using the therapy.”
Traders will note some softness in PMCB shares of late, with about -8% pushed out of share prices for the stock over the past week. But market participants may want to pay attention to this stock. PMCB is a stock who’s past is littered with sudden rips. Furthermore, the listing has seen interest climb, with an increase in recent trading volume of 29% over what the stock has registered over the longer term. Since we last covered the name, the stock has moved -20.3% to the downside, but the move counters a dramatic rise in shares in the Fall.
Currently trading at a market capitalization of $92M, PMCB has a store ($1.6M) of cash on the books, which is balanced by virtually no total current liabilities. The company is pre-revenue at this point. We will update the story again soon as developments transpire. For continuing coverage on shares of $PMCB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!